Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference44 articles.
1. Nexavar (sorafenib) FDA Approval History. Drugs.com. Available from: https://www.drugs.com/history/nexavar.html Accessed 24 November 2019.
2. Blumenschein G. Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol. 2008;3:S124–7.
3. Liang Y, Chen J, Yu Q, Ji T, Zhang B, Xu J, et al. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. Cancer Med. 2017;6:2787–95.
4. Sheng X, Huang T, Qin J, Li Q, Wang W, Deng L, et al. Preparation, pharmacokinetics, tissue distribution and antitumor effect of sorafenib-incorporating nanoparticles in vivo. Oncol Lett. 2017;14:6163–9.
5. Chen C, Ju R, Shi J, Chen W, Sun F, Zhu L, et al. Carboxyamidotriazole synergizes with Sorafenib to combat non–small cell lung cancer through inhibition of NANOG and aggravation of apoptosis. J Pharmacol Exp Ther. 2017;362:219–29.
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献